NVCR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Novocure's Optune Pax received CE Mark for locally advanced pancreatic cancerJul 1, 2026
- Novocure reported topline Phase 3 TRIDENT trial results evaluating earlier use of Tumor Treating Fields in newly diagnosed glioblastomaJun 18, 2026
- Novocure reported positive Phase 2 PANOVA-4 results for TTFields therapy in metastatic pancreatic cancerMar 26, 2026
- Novocure announced reimbursement approval in Japan for Optune Lua® in non-small cell lung cancerMar 2, 2026
- The FDA approved Novocure’s Optune Pax for treating locally advanced pancreatic cancerFeb 12, 2026